ReviewAnticancer research2016
Using Epigenetic Therapy to Overcome Chemotherapy Resistance.
Review in Anticancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 42 citations in OpenAlex.
- N-(2-Hydroxyphenyl)-2-propylpentanamide Modulates HDAC1 and GPER1 Expression in a Rodent Model of Triple-Negative Breast Cancer.Biomedicines · 2026Article
- Multi-step genomics on single cells and live cultures in sub-nanoliter capsules.bioRxiv : the preprint server for biology · 2025Article
- Identification of FLYWCH1 as a regulator of platinum-resistance in epithelial ovarian cancer.NAR cancer · 2025Article
- Targeting histone acetylation to overcome drug resistance in the parasitebioRxiv : the preprint server for biology · 2025Article
- Chemotherapy-Mediated Complications of Wound Healing: An Understudied Side Effect.Advances in wound care · 2024Review
- Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer.BMC cancer · 2024Article
- Establishment of Chemotherapy Prediction Model Based on Hypoxia-Related Genes for Oral Cancer.Journal of Cancer · 2024Article
- Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer.World journal of surgical oncology · 2023Article
- METTL1/WDR4-mediated tRNA mOncogene · 2023Article
- Synergistic combination of doxorubicin with hydralazine, and disulfiram against MCF-7 breast cancer cell line.PloS one · 2023Article
- Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.American journal of hematology · 2022Article
- Review
- Article
- Review
- Brain Tumor Biobank Development for Precision Medicine: Role of the Neurosurgeon.Frontiers in oncology · 2021Article
- Endometriosis and ovarian cancer risk, an epigenetic connection.Annals of translational medicine · 2020Review
- Cancer-Associated Fibroblasts: Epigenetic Regulation and Therapeutic Intervention in Breast Cancer.Cancers · 2020Review
- Review
- A Glioblastoma Genomics Primer for Clinicians.Medical research archives · 2020Article
- Epidrug Repurposing: Discovering New Faces of Old Acquaintances in Cancer Therapy.Frontiers in oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
It has been known for decades that as cancer progresses, tumors develop genetic alterations, making them highly prone to developing resistance to therapies. Classically, it has been thought that these acquired genetic changes are fixed. This has led to the paradigm of moving from one cancer therapy to the next while avoiding past therapies. However, emerging data on epigenetic changes during tumor progression and use of epigenetic therapies have shown that epigenetic modifications leading to chemotherapy resistance have the potential to be reversible with epigenetic therapy. In fact, promising clinical data exist that treatment with epigenetic agents can diminish chemotherapy resistance in a number of tumor types including chronic myelogenous leukemia, colorectal, ovarian, lung and breast cancer. The potential for epigenetic-modifying drugs to allow for treatment of resistant disease is exciting and clinical trials have just begun to evaluate this area.
Indexed as
Identifiers
26722021PMC6388403W2202593982What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.